References
- Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, et al. A multicenter, double-blind, randomized, placebo con-trolled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Ftheumatol 2006;33: 37–44.
- Debandt M, Vittecoq 0, Descamps V, Le Loet X, Meyer 0. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Ftheumatol 2003;22:56–61.
- Musial J, Undas A, Celinska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Ftheumatology 2003;42:1566–8.
- Shichijo K, Mitsui T, Kunishige M, Kuroda Y, Masuda K, Matsumoto T. Involvement of mitochondria in myasthenia gravis complicated with dermatomyositis and rheumatoid arthritis: a case report. Acta Neuropathol 2005;109:539–42.
- Jenkins EA, Hull RG, Thomas AL. D-penicillamine and polymyo-sitis: the significance of the anti-Jo-1 antibody. Br J Ftheumatol 1993;32: 1109–10.
- Hengstman GJ, van den Hoogen FH, Barrera P, Netea MG, Pieterse A, van de Putte LB, et al. Successful treatment of dermato-myositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 2003;50:10–5.
- Roddy E, Courtney PA, Morris A. Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Ftheumatology 2002;41:1194–5.
- Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy. J Ftheumatol 2006;33:24–30.
- Schmidt WA, Wetzel W, Friedlander R, Lange R, Sorensen HF, Lichey HJ, et al. Clinical and serological aspects of patients with anti-Jo-1 antibodies — an evolving spectrum of disease manifesta-tions. Clin Ftheumatol 2000;19:371–7.